BioPharma Resources

Drug Trial Radar · NCT07876492

A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Cenvacibart (REGN7508), a Monoclonal Antibody Against Factor XI, for Secondary Stroke Prevention (ROXI-DAISEN)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 6,106 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

6,106

Planned (sponsor's estimate)

Start

Nov 20, 2026

Primary completion

Dec 15, 2029

Study completion Dec 15, 2029

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test an experimental Regeneron drug called cenvacibart (REGN7508) ("study drug") compared with a placebo (a look-alike treatment with no active medicine) on top of background antiplatelet medications. The purpose of this study is to find out if cenvacibart can safely reduce the risk of another ischemic stroke or another blood clot related events in people who have recently had an ischemic stroke or mini-stroke (TIA). The study is looking at: * How well cenvacibart works * What side effects cenvacibart might cause * How much cenvacibart is in the blood at different times * How the body reacts to cenvacibart * How cenvacibart could affect the blood which can help researchers understand why cenvacibart works better in some people than others

Conditions

  • Secondary Stroke

Interventions

  • CenvacibartDrug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of ischemic strokeTime frame: Approximately 33 months
  2. Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleedingTime frame: Approximately 33 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.